{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:38:44Z","timestamp":1774607924713,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R01 HS024412"],"award-info":[{"award-number":["R01 HS024412"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Joint Commission Journal on Quality and Patient Safety"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jcjq.2018.12.003","type":"journal-article","created":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T04:47:39Z","timestamp":1548564459000},"page":"348-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications"],"prefix":"10.1016","volume":"45","author":[{"given":"Sarah","family":"Patterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2687-5043","authenticated-orcid":false,"given":"Gabriela","family":"Schmajuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishita","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zara","family":"Izadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8351-4626","authenticated-orcid":false,"given":"Milena","family":"Gianfrancesco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinoos","family":"Yazdany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.jcjq.2018.12.003_bb0005","doi-asserted-by":"crossref","first-page":"v48","DOI":"10.1093\/rheumatology\/kes122","article-title":"Developing an effective treatment algorithm for rheumatoid arthritis","volume":"51","author":"Keystone","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jcjq.2018.12.003_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.jcjq.2018.12.003_bb0015","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","article-title":"American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease","volume":"145","author":"Terdiman","year":"2013","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jcjq.2018.12.003_bb0020","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.15665","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017","volume":"177","author":"Smith","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jcjq.2018.12.003_bb0025","first-page":"625","article-title":"et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res","volume":"64","author":"Singh","year":"2012"},{"issue":"6","key":"10.1016\/j.jcjq.2018.12.003_bb0030","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 6","key":"10.1016\/j.jcjq.2018.12.003_bb0035","doi-asserted-by":"crossref","first-page":"vi37","DOI":"10.1093\/rheumatology\/kes283","article-title":"Overview of safety of non-biologic and biologic DMARDs","volume":"51","author":"Ruderman","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jcjq.2018.12.003_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1756-185X.12539","article-title":"Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan","volume":"17 Suppl 3","author":"Chiu","year":"2014","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"10.1016\/j.jcjq.2018.12.003_bb0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.semarthrit.2008.10.002","article-title":"The risk of infections with biologic therapies for rheumatoid arthritis","volume":"39","author":"Furst","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jcjq.2018.12.003_bb0050","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.berh.2015.05.009","article-title":"Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis","volume":"29","author":"Lahiri","year":"2015","journal-title":"Best Pract Res Clin 5Rheumatol"},{"issue":"4","key":"10.1016\/j.jcjq.2018.12.003_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153217","article-title":"Different risk of tuberculosis and efficacy of isoniazid prophylaxis in rheumatoid arthritis patients with biologic therapy: a Nationwide retrospective cohort study in Taiwan","volume":"11","author":"Liao","year":"2016","journal-title":"PLoS One."},{"issue":"3","key":"10.1016\/j.jcjq.2018.12.003_bb0060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1517\/14740338.2015.993605","article-title":"Safety issues and concerns of new immunomodulators in rheumatology","volume":"14","author":"Selmi","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"10.1016\/j.jcjq.2018.12.003_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166339","article-title":"One-year tuberculosis risk in rheumatoid arthritis patients starting their first tumor necrosis factor inhibitor therapy from 2008 to 2012 in Taiwan: a Nationwide population-based cohort study","volume":"11","author":"Lim","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jcjq.2018.12.003_bb0070","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ncprheum0336","article-title":"Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor","volume":"2","author":"Winthrop","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"7","key":"10.1016\/j.jcjq.2018.12.003_bb0075","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nrrheum.2009.105","article-title":"Preventing and treating biologic-associated opportunistic infections","volume":"5","author":"Winthrop","year":"2009","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.jcjq.2018.12.003_bb0080","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1016\/j.jcjq.2018.12.003_bb0085","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.2015.2571","article-title":"Preventing hepatitis B reactivation due to immunosuppressive drug treatments","volume":"313","author":"Perrillo","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jcjq.2018.12.003_bb0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"issue":"36","key":"10.1016\/j.jcjq.2018.12.003_bb0095","doi-asserted-by":"crossref","first-page":"10274","DOI":"10.3748\/wjg.v21.i36.10274","article-title":"Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations","volume":"21","author":"Mori","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jcjq.2018.12.003_bb0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5152\/eurjrheum.2015.150072","article-title":"Viral hepatitis screening guideline before biological drug use in rheumatic patients","volume":"3","author":"Karadag","year":"2016","journal-title":"Eur J Rheumatol"},{"issue":"5","key":"10.1016\/j.jcjq.2018.12.003_bb0105","first-page":"724","article-title":"Risk of hepatitis B virus reactivation in patients with inflammatory arthritis receiving disease-modifying antirheumatic drugs: A systematic review and meta-analysis. Arthritis","volume":"70","author":"Lin","year":"2018","journal-title":"Care Res"},{"issue":"2","key":"10.1016\/j.jcjq.2018.12.003_bb0110","first-page":"41","article-title":"Risk of tuberculosis reactivation with rituximab therapy","volume":"11","author":"Alkadi","year":"2017","journal-title":"Int J Health Sci (Qassim)"},{"issue":"10","key":"10.1016\/j.jcjq.2018.12.003_bb0115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11926-015-0539-7","article-title":"Cell therapies approved and emerging: a review of infectious risk and prevention during use","volume":"17","author":"MdYusof","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jcjq.2018.12.003_bb0120","unstructured":"United States Food and Drug Administration. FDA Highlights of Prescribing Information for Rituximab. Accessed Jul 19, 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103705s5367s5388lbl.pdf."},{"key":"10.1016\/j.jcjq.2018.12.003_bb0125","unstructured":"United States Food and Drug Administration. FDA highlights of prescribing information for Anakinra. Accessed Jul 19, 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103950s5136lbl.pdf."},{"key":"10.1016\/j.jcjq.2018.12.003_bb0130","unstructured":"United States Food and Drug Administration. FDA highlights of prescribing information for tocilizumab. Accessed Jul 19, 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103950s5136lbl.pdf."},{"key":"10.1016\/j.jcjq.2018.12.003_bb0135","unstructured":"United States Food and Drug Administration. FDA highlights of prescribing information for tofacitinib. Accessed Jul 19, 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203214s000lbl.pdf."},{"issue":"Suppl 5","key":"10.1016\/j.jcjq.2018.12.003_bb0140","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/rheumatology\/kes114","article-title":"Assessing the safety of biologic agents in patients with rheumatoid arthritis","volume":"51","author":"Rubbert-Roth","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jcjq.2018.12.003_bb0145","article-title":"Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis","author":"Baek","year":"2018","journal-title":"Korean J Intern Med"},{"issue":"6","key":"10.1016\/j.jcjq.2018.12.003_bb0150","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcjq.2018.12.003_bb0155","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/art.40176","article-title":"Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.jcjq.2018.12.003_bb0160","first-page":"531","article-title":"Safety profile of anakinra in the management of rheumatologic","volume":"34","author":"Lopalco","year":"2016","journal-title":"metabolic and autoinflammatory disorders Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.jcjq.2018.12.003_bb0165","first-page":"541","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jcjq.2018.12.003_bb0170","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/rheumatology\/kew329","article-title":"Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies","volume":"56","author":"Schulze-Koops","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jcjq.2018.12.003_bb0175","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40744-016-0049-8","article-title":"Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis: a post hoc analysis","volume":"4","author":"Soubrier","year":"2017","journal-title":"Rheumatol Ther"},{"issue":"5","key":"10.1016\/j.jcjq.2018.12.003_bb0180","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jcjq.2018.12.003_bb0185","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.autrev.2008.05.002","article-title":"Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases","volume":"8","author":"Cavazzana","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.jcjq.2018.12.003_bb0190","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10067-013-2378-0","article-title":"Long-term safety of anti-TNF-alpha in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients","volume":"33","author":"Costa","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.jcjq.2018.12.003_bb0195","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3899\/jrheum.130658","article-title":"Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial","volume":"41","author":"Iannone","year":"2014","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.jcjq.2018.12.003_bb0200","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrrheum.2009.279","article-title":"Tumor necrosis factor blockade and the risk of viral infection","volume":"6","author":"Kim","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.jcjq.2018.12.003_bb0205","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/1756-185X.12467","article-title":"The long-term effects of anti-TNF-alpha agents on patients with chronic viral hepatitis C and B infections","volume":"18","author":"Temel","year":"2015","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.jcjq.2018.12.003_bb0210","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jcjq.2018.12.003_bb0215","unstructured":"Mulcahy AW, Hlavka HJ, Case SR. Biosimilar cost savings in the US. Accessed Apr 9 2018. https:\/\/www.rand.org\/pubs\/perspectives\/PE264.html."},{"key":"10.1016\/j.jcjq.2018.12.003_bb0220","unstructured":"PR Newswire. U.S. Prescription Drug Spending Increased 13.1 Percent in 2014, Driven by Hepatitis C and Compounded Medications. 2014. Accessed Apr 15, 2018. http:\/\/www.prnewswire.com\/news-releases\/us-prescription-drug-spending-increased-131-percent-in-2014-driven-by-hepatitis-c-and-compounded-medications-300047923.html."},{"issue":"5","key":"10.1016\/j.jcjq.2018.12.003_bb0225","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/acr.20167","article-title":"Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines?","volume":"62","author":"Yazdany","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"16","key":"10.1016\/j.jcjq.2018.12.003_bb0230","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.2015.2571","article-title":"Preventing Hepatitis B Reactivation Due to Immunosuppressive Drug Treatments","volume":"313","author":"Perrillo","year":"2015","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.jcjq.2018.12.003_bb0235","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006528","article-title":"Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab","volume":"96","author":"Schmajuk","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"15","key":"10.1016\/j.jcjq.2018.12.003_bb0240","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jcjq.2018.12.003_bb0245","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona","year":"2003","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.jcjq.2018.12.003_bb0250","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/acr.22984","article-title":"Development of the American College of Rheumatology's rheumatoid arthritis electronic clinical quality measures","volume":"68","author":"Yazdany","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jcjq.2018.12.003_bb0255","unstructured":"Schmajuk G, et al. Large variations in tuberculosis testing for new biologic users with rheumatoid arthritis among providers in the RISE registry [abstract]. Arthritis Rheumatol. (69 (suppl 10))."},{"issue":"10","key":"10.1016\/j.jcjq.2018.12.003_bb0260","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.dld.2014.07.006","article-title":"Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study","volume":"46","author":"van der Have","year":"2014","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.jcjq.2018.12.003_bb0265","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/RHU.0b013e3182937094","article-title":"Assessing process of Care in Rheumatoid Arthritis at McGill University hospitals","volume":"19","author":"Li","year":"2013","journal-title":"Jcr-J Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.jcjq.2018.12.003_bb0270","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s10067-014-2612-4","article-title":"The impact of hepatitis screening on diagnosis and treatment in rheumatoid arthritis","volume":"33","author":"Conway","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.jcjq.2018.12.003_bb0275","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3747\/co.v17i6.653","article-title":"Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement","volume":"17","author":"Lee","year":"2010","journal-title":"Curr Oncol"},{"issue":"8","key":"10.1016\/j.jcjq.2018.12.003_bb0280","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1007\/s10620-016-4118-1","article-title":"Gastroenterologists Have suboptimal hepatitis B virus screening rates in patients receiving immunosuppressive therapy","volume":"61","author":"Paul","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.jcjq.2018.12.003_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120749","article-title":"Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening","volume":"10","author":"Visram","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.jcjq.2018.12.003_bb0290","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","author":"Holroyd","year":"2018","journal-title":"Rheumatology (Oxford)"}],"container-title":["The Joint Commission Journal on Quality and Patient Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155372501830309X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155372501830309X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:58:10Z","timestamp":1761559090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155372501830309X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S155372501830309X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjq.2018.12.003","relation":{},"ISSN":["1553-7250"],"issn-type":[{"value":"1553-7250","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications","name":"articletitle","label":"Article Title"},{"value":"The Joint Commission Journal on Quality and Patient Safety","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjq.2018.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Joint Commission. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}